Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer
These findings suggest the different efficacy of first-line treatment regimens across varying levels of PD-L1 expression, and the molecular characteristics of patients with long-term benefits from immunotherapy.
Authors
- Niansong Qian (ORCID: https://orcid.org/0000-0002-3297-4294)
- Miaomiao Gou (ORCID: https://orcid.org/0000-0001-9622-1198)
- Zhikuan Wang (ORCID: https://orcid.org/0000-0002-7025-735X)
- Guanghai Dai (ORCID: https://orcid.org/0000-0001-7508-274X)
- Yong Zhang (ORCID: https://orcid.org/0000-0002-1303-0458)
- Bingfa Yan
Institutions
- Chinese Academy of Sciences (CN)
- Chinese PLA General Hospital (CN)
- Microbiology Institute of Shaanxi (CN)
- Institute of Microbiology (CN)
- Beijing Fengtai Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1007/s00262-025-04248-0
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00